Affinage

PRRX2

Paired mesoderm homeobox protein 2 · UniProt Q99811

Length
253 aa
Mass
27.1 kDa
Annotated
2026-06-10
21 papers in source corpus 16 papers cited in narrative 16 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

PRRX2 is a paired-related homeobox transcription factor that drives mesenchymal programs by directly binding target gene promoters and activating their transcription, functioning as a pro-EMT, pro-invasive, and pro-metastatic regulator across multiple cancers (PMID:28750408, PMID:40393577, PMID:41882765). Its oncogenic output converges on several developmental signaling axes: it sustains Wnt/β-catenin signaling by promoting nuclear β-catenin accumulation in breast and colon cancer, where Wnt-activator rescue restores invasion after PRRX2 loss (PMID:28750408, PMID:31471104); it amplifies Hedgehog signaling through direct transcriptional activation of GLI2 to suppress senescence and promote pancreatic cancer growth (PMID:40619170); and it transcriptionally activates downstream effectors including IL-6 (feeding IL-6/STAT3 and Treg-mediated immune modulation in hepatocellular carcinoma), ATOX1 (limiting cuproptosis), CNTN3, and GCH1 (PMID:34413167, PMID:40393577, PMID:41882765, PMID:36266731). Through GCH1-driven BH4 antioxidant production, PRRX2 suppresses ferroptosis in glioma stem cells, and its protein level is constrained by circLRFN5-directed ubiquitin-proteasomal degradation (PMID:36266731). PRRX2 expression is itself controlled upstream by KLF6, which binds the Prrx2 promoter in pituitary cells, and by miR-212-5p, which represses Prrx2 via its 3'-UTR (PMID:24881871, PMID:29216628). In normal physiology PRRX2 acts as a mesenchymal/progenitor regulator: myoblast exosome-delivered PRRX2 activates the MIR22HG promoter to drive YAP-dependent osteogenic differentiation of BMSCs, it activates Panx3 transcription in preodontoblasts, and it serves as a barrier to neural fate in fibroblasts whose attenuation enhances induced-neuron conversion (PMID:37081396, PMID:39733924, PMID:31255287).

Mechanistic history

Synthesis pass · year-by-year structured walk · 10 steps
  1. 2014 Medium

    Established an upstream transcriptional regulator of PRRX2, placing it within a defined pituitary gene network rather than treating it as an orphan factor.

    Evidence Promoter luciferase, EMSA, and siRNA knockdown of KLF6 in pituitary cells

    PMID:24881871

    Open questions at the time
    • Does not identify PRRX2's own direct target genes in pituitary
    • Physiological consequence of KLF6→PRRX2 axis in vivo not established
  2. 2017 Medium

    Defined PRRX2 as a pro-EMT effector controlled by miR-212-5p and acting through Wnt/β-catenin, providing the first mechanistic link between PRRX2 and metastatic phenotypes.

    Evidence 3'-UTR luciferase reporter, shRNA knockdown, invasion/migration assays, and xenografts in breast cancer cells

    PMID:28750408 PMID:29216628

    Open questions at the time
    • Direct promoter targets mediating Wnt activation not identified
    • Mechanism by which PRRX2 controls β-catenin nuclear translocation unresolved
  3. 2019 Medium

    Generalized the PRRX2–Wnt/β-catenin invasion axis to colon cancer with epistatic rescue, and separately revealed a normal role as a barrier to neural reprogramming in fibroblasts.

    Evidence Knockdown plus LiCl Wnt-rescue and liver-metastasis model in colon cancer cells; shRNA knockdown plus RNAseq during fibroblast-to-neuron conversion

    PMID:31255287 PMID:31471104

    Open questions at the time
    • Direct Wnt-pathway target genes still inferred from markers, not ChIP
    • Fibroblast gene-regulatory targets of PRRX2 not mapped
  4. 2021 Medium

    Identified PRRX2 as a direct transcriptional activator of IL-6, linking it to IL-6/STAT3 signaling and immune modulation in hepatocellular carcinoma.

    Evidence Overexpression/knockdown in HCC lines with xenograft and Cbs heterozygous knockout mouse models

    PMID:34413167

    Open questions at the time
    • Direct promoter occupancy at IL-6 not shown by ChIP in this entry
    • Whether CBS regulates PRRX2 directly or indirectly unresolved
  5. 2022 Medium

    Connected PRRX2 to redox/ferroptosis control and post-translational regulation, showing it activates GCH1/BH4 to suppress ferroptosis while being degraded via circLRFN5-directed ubiquitination.

    Evidence RIP, RNA pull-down, ubiquitination assay, ChIP, and luciferase in glioma stem cells

    PMID:36266731

    Open questions at the time
    • The E3 ligase mediating circLRFN5-dependent degradation not identified
    • Ubiquitination sites on PRRX2 unmapped
  6. 2022 Medium

    Implicated PRRX2 in therapy resistance, showing its activation confers enzalutamide resistance through CDK4/6/Rb/E2F and BCL2 pathways in prostate cancer.

    Evidence Genome-wide CRISPRa screen with CDK4/6 and BCL2 inhibitor validation in prostate cancer cells

    PMID:35405009

    Open questions at the time
    • Whether PRRX2 directly transactivates CDK4/6 or BCL2 genes not determined
    • Direct target promoters in prostate cancer not defined
  7. 2023 Medium

    Defined a physiological gain-of-function role: exosome-delivered PRRX2 directly activates MIR22HG transcription to drive YAP-dependent osteogenic differentiation.

    Evidence ChIP, RIP, luciferase, immunofluorescence, exosome delivery, and ovariectomy mouse model in BMSCs

    PMID:37081396

    Open questions at the time
    • How PRRX2 is loaded into myoblast exosomes unknown
    • Generality of PRRX2-MIR22HG-YAP axis beyond osteogenesis untested
  8. 2024 Medium

    Expanded the direct PRRX2 target repertoire to ATOX1 (cuproptosis suppression in HCC) and Panx3 (preodontoblast regulation), reinforcing its role as a sequence-specific promoter-binding activator.

    Evidence ChIP, luciferase, EMSA, JASPAR site analysis, siRNA knockdown, and rescue in HCC and dental papilla-derived cells

    PMID:39733924 PMID:40393577

    Open questions at the time
    • Consensus PRRX2 binding motif not derived across targets
    • Tissue-specificity of target selection not explained
  9. 2024 Low

    Linked PRRX2 to radiation-induced ferroptosis resistance in skin cells downstream of Marveld3 silencing.

    Evidence siRNA/overexpression with Fe2+/ROS/lipid-peroxidation assays and RNAseq in HaCaT and WS1 cells

    PMID:39434056

    Open questions at the time
    • Molecular mechanism linking PRRX2 to ferroptosis suppression in skin incompletely characterized
    • Direct PRRX2 targets controlling Fe2+/ROS not identified
  10. 2025 Medium

    Broadened the oncogenic signaling output of PRRX2 to Hedgehog (via GLI2), CNTN3-driven CRC metastasis, and TGF-β/Fibronectin-mediated ECM remodeling in pancreatic cancer.

    Evidence ChIP/luciferase and knockdown/rescue in pancreatic and colorectal cancer cells; single-cell/spatial transcriptomics with knockdown migration assay in PDAC

    PMID:40619170 PMID:41456929 PMID:41882765

    Open questions at the time
    • GLI2 and TGFB1 direct binding inferred without explicit Tier 1 confirmation in two entries
    • Integration of Wnt, Hedgehog, and TGF-β outputs by PRRX2 not mechanistically unified

Open questions

Synthesis pass · forward-looking unresolved questions
  • How PRRX2 selects context-specific promoter targets and integrates its convergence on Wnt, Hedgehog, and TGF-β signaling remains unresolved.
  • No defined consensus DNA-binding motif or genome-wide occupancy map
  • Cofactors directing tissue-specific target selection unknown
  • No structural model of PRRX2-DNA or PRRX2-cofactor complexes

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140110 transcription regulator activity 7 GO:0003677 DNA binding 5
Localization
GO:0005634 nucleus 4
Pathway
R-HSA-74160 Gene expression (Transcription) 6 R-HSA-1266738 Developmental Biology 4 R-HSA-162582 Signal Transduction 4 R-HSA-5357801 Programmed Cell Death 3
Partners

Evidence

Reading pass · 16 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2022 CircLRFN5 binds directly to PRRX2 protein and promotes its degradation via a ubiquitin-mediated proteasomal pathway; PRRX2 transcriptionally upregulates GCH1 expression in glioma stem cells, suppressing ferroptosis by generating the antioxidant tetrahydrobiopterin (BH4). RNA immunoprecipitation, RNA pull-down assay, ubiquitination assay, dual-luciferase reporter assay, chromatin immunoprecipitation assay, shRNA knockdown/overexpression in glioma stem cells Journal of experimental & clinical cancer research : CR Medium 36266731
2021 PRRX2 functions as a transcription factor for IL-6, and CBS-mediated suppression of PRRX2 reduces IL-6/STAT3 pathway activity, leading to reduced Treg infiltration and increased apoptosis in hepatocellular carcinoma. HCC cell line overexpression/knockdown, in vivo xenograft and Cbs heterozygous knockout mouse models, signaling pathway analysis Journal for immunotherapy of cancer Medium 34413167
2017 PRRX2 (Prrx2) is a direct target of miR-212-5p; miR-212-5p suppresses Prrx2 by binding its 3'-UTR, and Prrx2 overexpression partially rescues miR-212-5p-mediated suppression of EMT in triple-negative breast cancer cells. Luciferase reporter assay targeting 3'-UTR, Western blot, wound healing and Transwell invasion assays, overexpression rescue experiments Cellular physiology and biochemistry Medium 29216628
2017 Knockdown of Prrx2 induces mesenchymal-to-epithelial transition in breast cancer cells, prevents nuclear translocation of β-catenin, and inhibits Wnt/β-catenin signaling, suppressing invasion and migration in vitro and tumor growth in vivo. shRNA knockdown in breast cancer cell lines, Western blot for EMT and Wnt/β-catenin markers, in vitro invasion/migration assays, nude mouse xenograft Cellular physiology and biochemistry Medium 28750408
2019 PRRX2 knockdown in colon cancer cells inactivates Wnt/β-catenin signaling (reducing p-GSK3βSer9/GSK3β, nuclear/cytoplasmic β-catenin, TCF4, and Vimentin; increasing E-cadherin), suppresses invasion and migration in vitro, and reduces liver metastasis in vivo; the Wnt activator LiCl reverses the inhibitory effect of PRRX2 silencing. siRNA/shRNA knockdown in CT-26 and CMT93 colon cancer cells, Western blot, Transwell invasion/migration assay, liver-metastatic mouse model, LiCl pathway rescue Pathology, research and practice Medium 31471104
2022 PRRX2 activation in prostate cancer cells promotes enzalutamide resistance through alterations in the CDK4/6/Rb/E2F and BCL2 pathways, identified via a genome-wide CRISPR activation screen. Genome-wide CRISPRa screen in metastatic castration-sensitive prostate cancer cells, pathway analysis of CDK4/6/Rb/E2F and BCL2, CDK4/6 and BCL2 inhibitor treatment Cancer research Medium 35405009
2023 Myoblast-derived exosomal PRRX2 directly binds to the MIR22HG promoter and promotes its transcription and expression; MIR22HG then sponges miR-128 to enhance YAP nuclear translocation, thereby facilitating osteogenic differentiation of BMSCs. Dual-luciferase reporter assay, RIP assay, ChIP assay, immunofluorescence for YAP nuclear translocation, exosome isolation and delivery, siRNA knockdown, overexpression rescue in BMSCs, ovariectomy mouse model Molecular medicine Medium 37081396
2014 KLF6 specifically stimulates Prrx2 expression; KLF6 can bind to the Prrx2 promoter as shown by EMSA, and siRNA-mediated KLF6 knockdown reduces Prrx2 expression in pituitary cells. Promoter luciferase assay, electrophoretic mobility shift assay (EMSA), siRNA knockdown, immunohistochemistry The Journal of reproduction and development Medium 24881871
2019 Attenuation of PRRX2 (together with HEY2) significantly enhances the transdifferentiation of adult human skin fibroblasts to induced neurons when combined with ASCL1 overexpression and p53 knockdown, indicating PRRX2 functions as a barrier in the fibroblast gene regulatory network that suppresses neural fate acquisition. shRNA knockdown of PRRX2 in human skin fibroblasts, RNAseq comparison of skin vs lung fibroblasts during neuronal conversion, MAP2+ neuron quantification Biochemical and biophysical research communications Medium 31255287
2024 PRRX2 directly binds to the ATOX1 promoter and positively regulates ATOX1 transcription in hepatocellular carcinoma cells; PRRX2 knockdown inhibits cell proliferation, invasion, and EMT while promoting cuproptosis, effects partially reversed by ATOX1 overexpression. ChIP assay, dual-luciferase reporter assay, JASPAR-predicted binding site analysis, siRNA knockdown, overexpression rescue in HCC cell lines, xenograft model Cellular signalling Medium 40393577
2024 PRRX2 directly binds to the Panx3 promoter and positively regulates Panx3 expression in preodontoblasts; PRRX2 knockdown with siRNA inhibits Panx3 expression, and PRRX2 overexpression in HEK293 cells increases luciferase activity from a Panx3 promoter reporter. Dual-luciferase reporter assay, electrophoretic mobility shift assay (EMSA), siRNA knockdown in dental papilla-derived cells Journal of oral biosciences Medium 39733924
2025 PRRX2 directly enhances transcription of GLI2, activating the Hedgehog pathway; this inhibits tumor cell senescence and promotes proliferation, invasion, and metastasis in pancreatic cancer; Hedgehog pathway inhibitors or GLI2 silencing partially reverse PRRX2's oncogenic effects. ChIP/luciferase (implied by 'directly enhanced transcription'), shRNA knockdown and overexpression in pancreatic cancer cells, senescence assays, Hedgehog pathway inhibitor treatment, GLI2 silencing rescue Cancer science Low 40619170
2025 PRRX2 binds to the CNTN3 promoter and transcriptionally activates CNTN3 in colorectal cancer; PRRX2 knockdown reduces CNTN3 expression, reverses EMT markers, and suppresses metastatic phenotypes; rescue with CNTN3 overexpression restores these effects. Chromatin immunoprecipitation (ChIP), dual-luciferase reporter assay, shRNA knockdown and rescue overexpression in CRC cell lines, xenograft model Cell division Medium 41882765
2025 PRRX2 amplifies TGF-β signaling through transcriptional activation of TGFB1 and activates Fibronectin 1 to remodel the ECM in pancreatic ductal adenocarcinoma; PRRX2 knockdown reduces tumor cell migration in vitro. Single-cell RNA-seq and spatial transcriptomics, cell-to-cell communication network analysis, shRNA knockdown in PDAC cell lines, multicolor immunofluorescence staining Chinese medical journal Low 41456929
2020 Silencing Prrx2 in breast cancer cells inhibits nuclear β-catenin expression and downregulates Wnt/β-catenin signaling activity, suppressing cell proliferation in vitro and tumor growth in vivo. shRNA knockdown in MDA-MB-231 and MCF-7 cells, MTT proliferation assay, nude mouse xenograft, Western blot for β-catenin Zhonghua yi xue za zhi Low 32234171
2024 Silencing of Marveld3 leads to upregulation of PRRX2, which subsequently reduces intracellular Fe2+ and ROS levels and suppresses lipid peroxidation, thereby attenuating radiation-induced ferroptosis in skin cells. siRNA silencing of Marveld3, PRRX2 overexpression/siRNA in HaCaT and WS1 cells, MDA/Fe2+/ROS assays, BODIPY staining, RNA sequencing Molecular medicine Low 39434056

Source papers

Stage 0 corpus · 21 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2022 CircLRFN5 inhibits the progression of glioblastoma via PRRX2/GCH1 mediated ferroptosis. Journal of experimental & clinical cancer research : CR 133 36266731
2021 Cystathionine β-synthase mediated PRRX2/IL-6/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. Journal for immunotherapy of cancer 52 34413167
2017 MiR-212-5p Suppresses the Epithelial-Mesenchymal Transition in Triple-Negative Breast Cancer by Targeting Prrx2. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 49 29216628
2014 PRRX1 and PRRX2 distinctively participate in pituitary organogenesis and a cell-supply system. Cell and tissue research 45 24770895
2000 Human PRRX1 and PRRX2 genes: cloning, expression, genomic localization, and exclusion as disease genes for Nager syndrome. Mammalian genome : official journal of the International Mammalian Genome Society 42 11063257
2023 Myoblast-derived exosomal Prrx2 attenuates osteoporosis via transcriptional regulation of lncRNA-MIR22HG to activate Hippo pathway. Molecular medicine (Cambridge, Mass.) 38 37081396
2015 PRRX1- and PRRX2-positive mesenchymal stem/progenitor cells are involved in vasculogenesis during rat embryonic pituitary development. Cell and tissue research 35 25795141
2022 A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer. Cancer research 30 35405009
2019 Inhibition of PRRX2 suppressed colon cancer liver metastasis via inactivation of Wnt/β-catenin signaling pathway. Pathology, research and practice 18 31471104
2019 Attenuation of PRRX2 and HEY2 enables efficient conversion of adult human skin fibroblasts to neurons. Biochemical and biophysical research communications 17 31255287
2014 Expression of Krüppel-like factor 6, KLF6, in rat pituitary stem/progenitor cells and its regulation of the PRRX2 gene. The Journal of reproduction and development 13 24881871
2017 Silencing of Prrx2 Inhibits the Invasion and Metastasis of Breast Cancer both In Vitro and In Vivo by Reversing Epithelial-Mesenchymal Transition. Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 12 28750408
2024 Upregulation of PRRX2 by silencing Marveld3 as a protective mechanism against radiation-induced ferroptosis in skin cells. Molecular medicine (Cambridge, Mass.) 5 39434056
2025 Transcriptional regulation of ATOX1 by PRRX2 impacts the progression and cuproptosis of hepatocellular carcinoma. Cellular signalling 3 40393577
2025 Single-cell and bulk RNA-sequencing reveal PRRX2-driven cancer-associated fibroblast-mediated perineural invasion for predicting the immunotherapy outcome in colorectal cancer. Frontiers in cell and developmental biology 2 41089673
2025 PRRX2 Regulates GLI2 to Promote Proliferation, Invasion, and Metastasis by Inhibiting Senescence via Hedgehog Signaling. Cancer science 1 40619170
2024 Prrx2, the paired-related homeobox transcription factor, functions as a potential regulator of pannexin 3 expression in odontoblast differentiation. Journal of oral biosciences 1 39733924
2026 Clinicopathological Characteristics of PRRX1 and PRRX2 Genes Expressions in Colorectal Cancer Patients. Cellular and molecular biology (Noisy-le-Grand, France) 0 41684173
2026 PRRX2-CNTN3 axis promotes epithelial-to-mesenchymal transition and metastasis in colorectal cancer. Cell division 0 41882765
2025 Single-cell and spatial transcriptomics reveal the interaction between PRRX2-driven epithelial cells and SPP1+ macrophages in mediating gemcitabine resistance in pancreatic ductal adenocarcinoma. Chinese medical journal 0 41456929
2020 [Effects of Prrx2 gene silencing on the proliferation of breast cancer and its molecular mechanisms]. Zhonghua yi xue za zhi 0 32234171

Missed literature

Know a paper Affinage missed for PRRX2? Flag it for the maintainers and the community.

No submissions yet.